Close
Close

Bispecific Antibody Engineering Services

Bispecific Antibody Services Distributed under Public Domain, from Wiki.

Scientists from Creative Biolabs have successfully produced all three types of bispecific antibodies using well-established methods. According to customer's detailed requirements, Creative Biolabs will design and perform the most suitable approach to fulfil client's demands.

A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that it's composed of fragments of two different monoclonal antibodies and consequently binds to two different types of antigen. The most widely used application of this approach is in cancer immunotherapy, where BsMAbs are engineered that simultaneously binds to a cytotoxic cell (using a receptor like CD3) and a target like a tumour cell to be destroyed. Fig. 1 below presents various bispecific antibodies currently studied.

Fig.1 Different bispecific antibody formats. Fig.1 Various types of bispecific antibodies.1

Of the two paratopes that form the tops of the variable domains in bispecific antibody, one can be directed against a tumour antigen and the other against a T lymphocyte antigen like CD3. In the case of trifunctional antibodies, the intact Fc region additionally binds to a cell that expresses Fc receptors like macrophage, a natural killer cell or a dendritic cell. In summary, through bispecific antibody, the tumour cell is connected to one or two cells of the immune system, leading to their destruction.

Comparing to the ordinary monoclonal antibodies, the ordinary ones can't activate T lymphocytes. Because there are no Fc receptors on T lymphocytes, the Fc region of ordinary monoclonal antibody can't bind to them, and the Fab regions are already used for binding the tumour cells. As a result, the bispecific antibody shows advantage in cancer immunotherapy over ordinary monoclonal antibody. Besides, bispecific antibodies have a higher cytotoxic potential. They are able to bind antigen that are expressed relatively weakly. It's common that bispecific antibody can have an effective dose several orders of magnitude lower than ordinary antibodies.

Reference

  1. Kang, Jingyue, Tonglin Sun, and Yan Zhang. "Immunotherapeutic progress and application of bispecific antibody in cancer." Frontiers in Immunology 13 (2022): 1020003. Distributed under Open Access license CC BY 4.0, without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us